Last update 20 Mar 2025

ATG-022

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
+ [1]
Action
inhibitors
Mechanism
CLDN18.2 inhibitors(Claudin 18.2 inhibitors), Tubulin inhibitors
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC11H22N4O4
InChIKeyAGGWFDNPHKLBBV-YUMQZZPRSA-N
CAS Registry159858-33-0
View All Structures (2)
Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Gastric CarcinomaPhase 2
China
20 Mar 2024
Metastatic Gastric CarcinomaPhase 2
Australia
20 Mar 2024
CLDN18.2 positive Solid TumorsPhase 1
China
10 May 2023
Advanced Malignant Solid NeoplasmPhase 1
China
27 Mar 2023
Advanced Malignant Solid NeoplasmPhase 1
Australia
27 Mar 2023
Stomach CancerPreclinical
United States
22 May 2023
Pancreatic CancerPreclinical
United States
16 May 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
37
(dose escalation phase)
(yfjipkobqv) = in dose escalation, 1 DLT of grade 3 nausea found at 3 mg/kg among 6 pts pgqupgzsce (qdqgherthv )
Positive
23 Jan 2025
(dose expansion phase)
NEWS
ManualManual
Phase 2
12
(dtgupwwgyb) = pwtpwwnehr bnyswsyjjn (vnvgawqcgy )
Positive
23 Aug 2024
(Claudin18.2中高表达)
(dtgupwwgyb) = fovplkhnsx bnyswsyjjn (vnvgawqcgy )
Phase 1
10
ATG-022 0.9 mg/kg
(nlfrgmgqkz) = bgezlqelfl oqrwefdemy (lbjduumyaz )
-
24 May 2024
ATG-022 1.8 mg/kg
(nlfrgmgqkz) = pcasywtttf oqrwefdemy (lbjduumyaz )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free